Skip to main content
File #: 4119   
Type: Consent Status: Passed
File created: 5/10/2021 Department: Arrowhead Regional Medical Center
On agenda: 5/18/2021 Final action: 5/18/2021
Subject: Amendment to Custom Cost-Per-Reportable Agreement with Sysmex America Inc. for the Usage of a Hematology Automation System
Attachments: 1. CON - ARMC - 5-18-21- Amendment to Agreement with Sysmex A-1, 2. Item #11 Executed BAI, 3. 21-355-A-1 Executed Contract
REPORT/RECOMMENDATION TO THE BOARD OF SUPERVISORS
OF THE COUNTY OF SAN BERNARDINO
AND RECORD OF ACTION

May 18, 2021

FROM
WILLIAM L. GILBERT, Director, Arrowhead Regional Medical Center

SUBJECT
Title
Amendment to Custom Cost-Per-Reportable Agreement with Sysmex America Inc. for the Usage of a Hematology Automation System
End

RECOMMENDATION(S)
Recommendation
Approve Amendment No. 1 to the Custom Cost-Per-Reportable Agreement (Contract No. 4400003653) with Sysmex America Inc., to increase the amount by $300,000, from $1,073,102 to $1,373,102, and to clarify the agreement term of May 23, 2018 through May 22, 2023, for the continued usage of the Hematology Automation System.
(Presenter: William L. Gilbert, Director, 580-6150)
Body

COUNTY AND CHIEF EXECUTIVE OFFICER GOALS & OBJECTIVES
Provide for the Safety, Health and Social Service Needs of County Residents.

FINANCIAL IMPACT
Approval of this item will not result in the use of Discretionary General Funding (Net County Costs). The additional cost of $300,000 is funded by State Medi-Cal, Federal Medicare, private insurances and other departmental revenues. Funding sources may change in the future pending any legislative activity related to the repeal and/or replacement of the Affordable Care Act. Adequate appropriation and revenue have been included in the Arrowhead Regional Medical Center (ARMC) 2020-21 budget and will be included in future recommended budgets.

BACKGROUND INFORMATION
Approval of this item will allow ARMC the continued use of the Sysmex America Inc. (Sysmex) Hematology Automation System (System). The System is used for routine screening, diagnosis of hematological conditions including anemia and leukemia, diagnosis relating to the management of blood loss and transfusions, and diagnosis of sepsis. Increased demand for these types of diagnostics test has resulted in the need to increase the agreement amount.

On October 31, 2017 (Item No. 10), the Board of Supervisors autho...

Click here for full text